Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients [ 2014 - 2018 ]

Research Grant

Researchers: Prof Alexander Thompson (Principal investigator) ,  A/Pr Paul Desmond ,  A/Pr Vijaya Sundararajan ,  Prof Kumar Visvanathan ,  Prof Stephen Locarnini
View all 6 related researchers

Brief description Guidelines currently recommend lifelong treatment for patients with chronic hepatitis B, with associated cost and risks of drug resistance and side effects. It has recently been suggested that up to 50% of patients may safely and successfully stop drug after long-term treatment. Our project will identify which patients can safely stop treatment, by performing detailed studies of the human immune system and the hepatitis B virus. This will be an important advance for patient care.

Funding Amount $AUD 976,778.05

Funding Scheme Project Grants

Notes Standard Project Grant